China’s NMPA grants clearance for Biosyngen’s nasopharyngeal carcinoma trial
In a Phase I trial, BRG01 demonstrated promising results with a 75% response rate in high-dose patients.
Regulation
New Labour government backs pharma reform in UK
Pharma sector votes for post-Brexit clarity under new government
FDA issues draft guidance on diversity action plans for trials
UK’s clinical landscape faces new reality as international competition heats up
Europe updates CTIS to support more transparent trial reporting
FDA places partial clinical hold on Zentalis’ trials of azenosertib for cancer
UK clinical trial sector must address prolonged timelines, say experts
